Detail akcie BioVie Rg-A online

Business Summary: BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Financial Summary: BRIEF: For the six months ended 31 December 2025, BioVie Inc revenues was not reported. Net loss applicable to common stockholders decreased 4% to $11.2M. Lower net loss reflects Selling, general and administrativ decrease of 15% to $3.6M (expense), Interest Expense decrease of 98% to $8K (expense), Change in fair value of derivative liab. decrease from $4K (expense) to $0K.